This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
What Lies in Store for Healthcare ETFs in Q3 Earnings?
by Sweta Killa
Big stocks are likely to dominate the returns of the healthcare ETF going into Q3 earnings announcements.
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
by Sweta Killa
Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
ETFs in Focus Amid September's Market Storm Possibilities
by Yashwardhan Jain
The "September Effect" adds to the volatility already present in the market, increasing the need for investors to adopt a cautious approach when maintaining their portfolios.
Defensive ETFs Shine Amid a Rough Start to September
by Sweta Killa
Defensive sector ETFs achieve new highs amid a dull start to September.
5 ETFs to Make the Most of Eli Lilly's Strength
by Sweta Killa
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
ETFs to Secure Your Portfolio Amid Uncertain Market Conditions
by Yashwardhan Jain
With the markets recently experiencing a sharp sell-off which may have dampened investor confidence, increasing bets that the U.S. economy may slip into a recession increases the need to safeguard investor portfolios with defensive bets.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
UnitedHealth Rises on Q2 Earnings Beat: ETFs to Gain
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected second-quarter 2024 results as it breezed past the Zacks Consensus Estimate on both earnings and revenues.